Definition · Plain-language
Supplemental NDA (sNDA)
A Supplemental New Drug Application (sNDA) is the application a sponsor files to change an already-approved drug, such as adding a new indication, formulation or labelling change.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What an sNDA changes
Once a drug is approved through a New Drug Application, any significant change to it is generally handled through a supplement rather than a brand-new application. A Supplemental NDA can seek to add a new approved use (indication), introduce a new dosage form or strength, change the formulation, alter the manufacturing process or facility, or revise the labelling. The supplement is tied to the original NDA and lets the sponsor expand or modify an approved product without starting the application process over from the beginning.
How supplements are reviewed
The FDA categorises supplements by the type and significance of the change. Some changes — for example adding a major new indication — require prior FDA approval before they can be implemented, and these "prior approval supplements" undergo substantive review of supporting data, which for a new indication typically includes clinical trial evidence. Other, lower-risk changes can be implemented under "changes being effected" procedures or reported in an annual report. The principle is that the level of FDA scrutiny scales with the potential impact of the change.
Why sNDAs matter
Supplemental NDAs are the mechanism by which approved drugs evolve over their lifecycle: gaining new indications, improving formulations, or updating safety information in the labelling as new data emerge. Because a new indication can substantially change how a drug is used, an efficacy supplement adding an indication is reviewed against an evidentiary standard comparable to an original approval for that use. This keeps approved products current while preserving the FDA’s oversight of any meaningful change.
Key facts
At a glance
- Definition: Application to change an already-approved drug under its NDA.
- Stands for: Supplemental New Drug Application.
- Common uses: New indication, formulation, dosage, manufacturing, labelling.
- Tied to: An existing approved New Drug Application.
- Review depth: Scales with the significance of the change.
- Reviewer: FDA — Center for Drug Evaluation and Research (CDER).
Common misconceptions
What people often get wrong
Often heard: An sNDA is a completely separate application from the original NDA.
Actually: A Supplemental NDA is filed against an existing approved NDA to change that product. It builds on the original application rather than replacing it with a wholly independent submission.
Often heard: Adding a new indication through an sNDA needs little or no new evidence.
Actually: An efficacy supplement to add a new indication generally requires substantial new data, often including clinical trials, and is reviewed against a standard comparable to an original approval for that use.
Often heard: All changes to an approved drug require a prior-approval supplement.
Actually: The FDA scales review to the change. Some changes need prior approval, others can proceed under "changes being effected" procedures, and minor changes may simply be noted in an annual report.
Going deeper
